INCB106385 + INCMGA00012

INCB106385 + INCMGA00012 is a combination therapy under clinical investigation for advanced solid tumors. **INCB106385** is an investigational oral small molecule, with activity likely as an immunomodulatory agent, studied alone or in combination. **INCMGA00012**, also known as retifanlimab, is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), functioning as a checkpoint inhibitor to boost T-cell activity and the immune response against cancer cells. This combination aims to enhance anti-tumor immune activation in cancers expressing CD8 T cells and is being explored for a range of solid tumors including bladder, breast, colorectal, esophageal, ovarian, head and neck, lung, pancreatic, and prostate cancers[1][3][5][7][9].

Other names

retifanlimab